Targeting Cancer: Microenvironment and Immunotherapy Innovations DOI Open Access
Irena Padzińska-Pruszyńska, Bartłomiej Taciak, Łukasz Kiraga

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13569 - 13569

Published: Dec. 18, 2024

In 2024, the United States was projected to experience 2 million new cancer diagnoses and approximately 611,720 cancer-related deaths, reflecting a broader global trend in which cases are anticipated exceed 35 by 2050. This increasing burden highlights ongoing challenges treatment despite significant advances that have reduced mortality 31% since 1991. Key obstacles include disease’s inherent heterogeneity complexity, such as resistance, stem cells, multifaceted tumor microenvironment (TME). The TME—comprising various immune blood vessels, biochemical factors—plays crucial role growth resistance therapies. Recent innovations treatment, particularly field of immuno-oncology, leveraged insights into TME interactions. An emerging example is FDA-approved therapy using tumor-infiltrating lymphocytes (TILs), demonstrating potential cell-based approaches solid tumors. However, TIL just one many strategies being explored. review provides comprehensive overview focusing on how novel therapies targeting or harnessing components could enhance efficacy address persistent care.

Language: Английский

DNA Repair Pathways in the Mitochondria DOI
Dillon E. King, William C. Copeland

DNA repair, Journal Year: 2025, Volume and Issue: 146, P. 103814 - 103814

Published: Feb. 1, 2025

Language: Английский

Citations

2
Cancer Metastasis‐on‐a‐Chip for Modeling Metastatic Cascade and Drug Screening DOI Creative Commons
Anastasia Brooks, Yali Zhang, Jiezhong Chen

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(21)

Published: Jan. 15, 2024

Microfluidic chips are valuable tools for studying intricate cellular and cell-microenvironment interactions. Traditional in vitro cancer models lack accuracy mimicking the complexities of vivo tumor microenvironment. However, cancer-metastasis-on-a-chip (CMoC) combine advantages 3D cultures microfluidic technology, serving as powerful platforms exploring mechanisms facilitating drug screening. These able to compartmentalize metastatic cascade, deepening understanding its underlying mechanisms. This article provides an overview current CMoC models, focusing on distinctive that simulate invasion, intravasation, circulation, extravasation, colonization, their applications Furthermore, challenges faced by technologies discussed, while promising future directions research. The ongoing development integration these into studies expected drive transformative advancements field.

Language: Английский

Citations

11
Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles DOI Open Access
Muttiah Barathan, Ahmad Khusairy Zulpa, Sook Luan Ng

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7470 - 7470

Published: July 8, 2024

Colorectal cancer (CRC) is a significant public health challenge, with 5-fluorouracil (5-FU) resistance being major obstacle to effective treatment. Despite advancements, 5-FU remains formidable due complex mechanisms such as alterations in drug transport, evasion of apoptosis, dysregulation cell cycle dynamics, tumor microenvironment (TME) interactions, and extracellular vesicle (EV)-mediated pathways. Traditional chemotherapy often results high toxicity, highlighting the need for alternative approaches better efficacy safety. Phytochemicals (PCs) EVs offer promising CRC therapeutic strategies. PCs, derived from natural sources, exhibit lower toxicity can target multiple pathways involved progression resistance. facilitate targeted delivery, modulate immune response, interact TME sensitize cells However, potential PCs engineered overcoming reshaping immunosuppressive underexplored. Addressing this gap crucial identifying innovative therapies enhanced reduced toxicities. This review explores multifaceted evaluates synergistic effects combining improve treatment while minimizing adverse effects. Additionally, it investigates by serving delivery vehicles modulating TME. By synthesizing current knowledge addressing research gaps, enhances academic understanding CRC, interdisciplinary involving revolutionizing therapy. Further clinical validation are essential translating these findings into improved patient outcomes.

Language: Английский

Citations

6
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Citations

6
CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms DOI Creative Commons
Raanan Greenman, Chris J. Weston

Cells, Journal Year: 2025, Volume and Issue: 14(2), P. 105 - 105

Published: Jan. 13, 2025

Tissue fibrosis results from a dysregulated and chronic wound healing response accompanied by inflammation angiogenesis. Regardless of the affected organ, shares following common hallmarks: recruitment immune cells, fibroblast activation/proliferation, excessive extracellular matrix deposition. Chemokines play pivotal role in initiating advancing these fibrotic processes. CCL24 (eotaxin-2) is chemokine secreted cells epithelial which promotes trafficking activation profibrotic through CCR3 receptor binding. Higher levels were found tissue sera patients with fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), metabolic dysfunction-associated steatohepatitis (MASH). This review delves into intricate highlighting its impact on fibrotic, immune, vascular pathways. We focus preclinical clinical evidence supporting therapeutic potential blocking diseases that involve fibrosis.

Language: Английский

Citations

0
Differences in treatment outcome between translational platforms in developing therapies for gastrointestinal cancers. DOI

Katarzyna Wawrzak-Pienkowska,

Tomasz Pienkowski, Anna Tankiewicz‐Kwedlo

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177309 - 177309

Published: Jan. 1, 2025

Language: Английский

Citations

0
Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance DOI Creative Commons
James Ingham, Jia-Ling Ruan, Matthew A. Coelho

et al.

BJC Reports, Journal Year: 2025, Volume and Issue: 3(1)

Published: Feb. 27, 2025

Abstract Most cancer-related deaths result from drug-resistant disease(1,2). However, cancer drug resistance is not a primary focus in development. Effectively mitigating and treating will require advancements multiple fields, including early detection, discovery, our fundamental understanding of biology. Therefore, successfully tackling requires an increasingly multidisciplinary approach. A recent workshop on resistance, jointly organised by Cancer Research UK, the Rosetrees Trust, UKRI-funded Physics Life Network, brought together experts cell biology, physical sciences, computational clinicians to these key challenges devise interdisciplinary approaches address them. In this perspective, we review outcomes highlight unanswered research questions. We outline emerging hallmarks discuss lessons COVID-19 pandemic antimicrobial that could help accelerate information sharing timely adoption discoveries into clinic. envisage initiatives drive greater interdisciplinarity yield rich dividends developing new ways better detect, monitor, treat thereby improving treatment for patients.

Language: Английский

Citations

0
LOX+ iCAFs in HNSCC have the potential to predict prognosis and immunotherapy responses revealed by single cell RNA sequencing analysis DOI Creative Commons

Xue Liu,

Huibing Li,

Yanjin Wang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 27, 2025

Carcinoma-associated fibroblasts (CAFs) exhibit significant heterogeneity and are closely associated with progression, resistance to anticancer therapies, poor prognosis in head neck squamous cell carcinoma (HNSCC). However, the specific functional role of CAFs HNSCC has been inadequately explored. In this study, we utilized a single-cell RNA sequencing dataset from (GSE103322) recluster via Seurat pipeline. On basis reported markers, identified two CAF subtypes, LOX-myCAFs LOX + iCAFs, generated signature markers for each. Through unsupervised consensus clustering, characterized molecular subtypes HNSCC-TCGA, each exhibiting distinct dysregulated cancer hallmarks, immunological tumor microenvironments, stemness characteristics. The robustness iCAF-related particularly terms prediction immunotherapeutic response, was validated an ANOVA cohort GEO (GSE159067) consisting 102 patients. A positive correlation between expression that CD86, marker M1 macrophage polarization. Further experiments involving coculture conditioned medium derived LOX-silenced CAL-27 UM-SCC-1 lines revealed silencing led decreased proliferation migration these cells, which mediated by epithelial-mesenchymal transition (EMT) through IL-34- induced CSF1R/Akt signaling. summary, our bulk analyses can predict response immunotherapy Additionally, gene as promising therapeutic target treatment.

Language: Английский

Citations

0
Nano-drug delivery strategies affecting cancer-associated fibroblasts to reduce tumor metastasis DOI Creative Commons

Linghui Zou,

Peng Xian,

Qing Pu

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Microambiente tumoral: influencia en el tratamiento del cáncer DOI Open Access
Pablo Cabral, Ximena Camacho

SALUD MILITAR, Journal Year: 2025, Volume and Issue: 44(1), P. e401 - e401

Published: March 10, 2025

La presente revisión aborda el microambiente tumoral como un objetivo terapéutico en tratamiento del cáncer. Discutimos tanto su composición influencia la progresión y resistencia tumoral; así también distintas estrategias terapéuticas dirigidas a modulación. Comprender las intrincadas interacciones dentro no solo es fundamental para entender biología cáncer, sino que clave futuro de terapias oncológicas, ofreciendo una nueva esperanza lucha contra esta enfermedad devastadora. Este artículo fue aprobado por Comité Editorial. Recibido evaluación: diciembre 2024.Aceptado publicación: 2024.Correspondencia: Facultad Ciencias. Mataojo 2055, C.P. 11400. Montevideo, Uruguay. Tel.: (+598) 099472572. E-mail contacto: [email protected]

Citations

0